BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1796756)

  • 1. Tissue and urokinase plasminogen activators in bone tissue and their regulation by parathyroid hormone.
    Leloup G; Peeters-Joris C; Delaisse JM; Opdenakker G; Vaes G
    J Bone Miner Res; 1991 Oct; 6(10):1081-90. PubMed ID: 1796756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
    Leloup G; Lemoine P; Carmeliet P; Vaes G
    J Bone Miner Res; 1996 Aug; 11(8):1146-57. PubMed ID: 8854251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA.
    Fukumoto S; Allan EH; Yee JA; Gelehrter TD; Martin TJ
    J Cell Physiol; 1992 Aug; 152(2):346-55. PubMed ID: 1322417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones.
    Leloup G; Delaisse JM; Vaes G
    J Bone Miner Res; 1994 Jun; 9(6):891-902. PubMed ID: 8079664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activators are involved in the degradation of bone by osteoclasts.
    Everts V; Daci E; Tigchelaar-Gutter W; Hoeben KA; Torrekens S; Carmeliet G; Beertsen W
    Bone; 2008 Nov; 43(5):915-20. PubMed ID: 18691680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the plasminogen system in bone resorption in vitro.
    Daci E; Udagawa N; Martin TJ; Bouillon R; Carmeliet G
    J Bone Miner Res; 1999 Jun; 14(6):946-52. PubMed ID: 10352103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-beta stimulates bone resorption in neonatal mouse calvariae by a prostaglandin-unrelated but cell proliferation-dependent pathway.
    Lerner UH
    J Bone Miner Res; 1996 Nov; 11(11):1628-39. PubMed ID: 8915770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intact insulin-like growth factor binding protein-5 (IGFBP-5) associates with bone matrix and the soluble fragments of IGFBP-5 accumulated in culture medium of neonatal mouse calvariae by parathyroid hormone and prostaglandin E2-treatment.
    Hakeda Y; Kawaguchi H; Hurley M; Pilbeam CC; Abreu C; Linkhart TA; Mohan S; Kumegawa M; Raisz LG
    J Cell Physiol; 1996 Feb; 166(2):370-9. PubMed ID: 8591997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
    Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
    J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
    España F; Estellés A; Fernández PJ; Gilabert J; Sánchez-Cuenca J; Griffin JH
    Thromb Haemost; 1993 Dec; 70(6):989-94. PubMed ID: 8165623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic AMP-dependent and -independent effects on tissue-type plasminogen activator activity in osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid hormone antagonists.
    Allan EH; Hamilton JA; Medcalf RL; Kubota M; Martin TJ
    Biochim Biophys Acta; 1986 Sep; 888(2):199-207. PubMed ID: 3017447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of transforming growth factor beta on the plasminogen activator activity of normal human osteoblast-like cells and a human osteosarcoma cell line MG-63.
    Fawthrop FW; Oyajobi BO; Bunning RA; Russell RG
    J Bone Miner Res; 1992 Dec; 7(12):1363-71. PubMed ID: 1481722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the role of cyclic AMP as a mediator of bone resorption: gamma-interferon completely inhibits cholera toxin- and forskolin-induced but only partially inhibits parathyroid hormone-stimulated 45Ca release from mouse calvarial bones.
    Lerner UH; Ransjö M; Ljunggren O; Klaushofer K; Hoffmann O; Peterlik M
    J Bone Miner Res; 1991 Jun; 6(6):551-60. PubMed ID: 1653515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schwann cell plasminogen activator is regulated by neurons.
    Clark MB; Zeheb R; White TK; Bunge RP
    Glia; 1991; 4(5):514-28. PubMed ID: 1834568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes.
    Seki T; Miyasu T; Noguchi T; Hamasaki A; Sasaki R; Ozawa Y; Okukita K; Declerck PJ; Ariga T
    J Cell Physiol; 2001 Oct; 189(1):72-8. PubMed ID: 11573206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue plasminogen activator binding to mouse cerebellar granule neurons.
    Verrall S; Seeds NW
    J Neurosci Res; 1988; 21(2-4):420-5. PubMed ID: 3145983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-type and tissue-type plasminogen activators have different distributions in cultured bovine capillary endothelial cells.
    Moscatelli D
    J Cell Biochem; 1986; 30(1):19-29. PubMed ID: 3082899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.